PDCD1 and hepatocellular carcinoma: In the above-mentioned study of regorafenib combined with anti-PD-1 therapy, researchers discovered that in an orthotopic mouse model of HCC, an intermediate dose (10 mg/kg) of regorafenib combined with anti-PD-1 therapy considerably decreased the region of hypoxia in comparison to other doses of regorafenib.